Power Law company profile

DIAGENS

Biotech & Life Sciences · Hangzhou, China · Founded 2016 · IPO 2026 Unicorn

Focusing on solving the core technical difficulties in the field of human reproductive health and providing high-tech products and services for clinical hospitals, research institutes and the public

Valuation

$3.09B

Market cap · May/2026

Revenue

$23M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

18 investors on DIAGENS's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage

Yuhang Fund

Zijingang Venture Capital

Series A 3 investors entered at this stage

Donghai Polymerization

Huadan Angel

Yueqing Deheng Investment

Series B+ 13 investors entered at this stage

China Venture Capital HRVC

Yingberli Investment

Meihong Investment

InterChina Partners

Zhejiang Shoucheng

Xiangjiang Liyuan Investment

Tenghua Assets

Shenzhen Guozhong Venture Capital Management

Meinian Onehealth

Peking University

Tsinghua University

Grand Flight Investment

Jiayuan Venture Capital

Global footprint

Where DIAGENS has talent and traffic

Workforce by country

🇨🇳 China · Hangzhou HQ

Book a demo for the full country breakdown

Web traffic by country

180 monthly visits
across markets

🇭🇰 Hong Kong111.1%

Top 1 markets shown

Market sentiment

What the market is saying about DIAGENS

An AI-synthesized read of the highest-engagement posts about DIAGENS on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See DIAGENS on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles